|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the angiotensin-converting enzyme (ACE) (insertion/deletion (I/D) in intron 16) and of the plasminogen activator inhibitor-1 (PAI-1) (promoter 4G/5G) genes have been linked with coronary heart disease (CHD) and/or myocardial infarction (MI).
|
11427204 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The 4G allele of the PAI-1 -675(4G/5G) insertion/deletion promoter polymorphism has been associated with elevated plasma levels of PAI-1 and an increased risk of myocardial infarction.
|
20806116 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our results showed that carriers of PAI-1 4G/5G genotype with myocardial infarction have increased odds of coronary artery occlusion more than 1.6 times in comparison to the carriers of homozygous genotypes.
|
26273123 |
2015 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
GJA4 1019 C > T, MMP3 -1171delA, and SERPINE1 -668delG genotypes have been associated with the risk of incident myocardial infarction.
|
17719307 |
2007 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In conclusion the PAI-1 gene polymorphism was found to have a gender specific role in the female MI patients.
|
21082259 |
2011 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Sixty-six patients with myocardial infarction and sixty-two healthy control patients were chosen for the analysis of the PAI-1 promoter 4G/5G genotype with polymerase chain reaction-single strand conformation polymorphism.
|
9622220 |
1998 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the fibrinogen -455A allele was significantly associated with a decreased risk of myocardial infarction (OR 0.66, 95% CI 0.44 to 0.99, P=0.04), whereas the PAI-1 4G4G genotype was significantly associated with increased risk (OR 1.20, 95% CI 1.04 to 1.39, P=0.04).
|
11748101 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that the 4G/5G gene polymorphism of PAI-1 is associated with myocardial infarction, that 4G/4G type is probably an important hereditary risk factor, and that glucose has functional importance in regulating PAI-1 activity.
|
11780311 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk.
|
8571307 |
1995 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Since 4G4G homozygotes of an insertion/deletion (4G/5G) gene variation in the promoter of PAI-I have been shown to have increased levels of PAI-I, we analysed the relation of this gene polymorphism to CAD and MI in a population of 2565 participants who underwent coronary angiography for diagnostic purposes.
|
10494775 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between the risk of myocardial infarction at a young age and genetic factors thought to be associated with an increased tendency to thrombosis (the polymorphisms 4G/5G of the PAI-1 gene, PIA1/PIA2 of the platelet glycoprotein IIIa, C3550T of the platelet glycoprotein Ib gene, G10976A of the factor VII gene, C677T of the methylenetetrahydrofolate reductase gene, G1691A of the factor V gene, and G20210A of the prothrombin gene), we performed a case-control study evaluating 200 survivors (185 men, 15 women) of myocardial infarction who had experienced the event before the age of 45 years and 200 healthy subjects with a negative exercise test, individually matched for sex, age, and geographic origin with the cases.
|
10381497 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We explored whether 4G/5G polymorphism of the PAI-1 gene is associated with the development of MI <or= 35 years of age.
|
19844663 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men.
|
9863707 |
1998 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We have prospectively evaluated the effect of plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphisms on the occurrence of MI in uraemics.
|
12748347 |
2003 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In essence, tagging polymorphisms, including the 4G/5G polymorphism, and common haplotypes of the SERPINE1 gene region were not associated with MI in a German sample, and no compelling evidence was obtained for a relationship of the 4G/5G polymorphism to MI and coronary atherosclerosis in a meta-analysis.
|
20352162 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis.
|
10073956 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.
|
10942788 |
2000 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
RGD |
Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.
|
16053971 |
2005 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
|
9285181 |
1997 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Myocardial infarction occurs with a similar 24 h pattern in the 4G/5G versions of plasminogen activator inhibitor-1.
|
19444746 |
2009 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
LHGDN |
Plasminogen activator inhibitor in patients with acute myocardial infarction and re-infarction in syndrome X.
|
11934213 |
2002 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functional variants of angiotensin-1-converting enzyme (ACE), beta-fibrinogen, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase, glycoprotein Illa, and many apolipoprotein genes are considered excellent candidate risk factors for MI.
|
9649939 |
1998 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Independent predictors of death were PAI-1 rise and final Thrombolysis in Myocardial Infarction flow.
|
29972733 |
2018 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
MPO and PAI-1 are shown to have a critical role in the LV response immediately after MI, as demonstrated by markedly delayed myocardial rupture in the MPO(-/-) and accelerated rupture in the PAI-1(-/-).
|
12615902 |
2003 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we provide evidence for an independent, etiological role of PAI-1 in myocardial infarction.
|
7892190 |
1995 |